Fondazione GONO G.I. — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

6 Recruiting

6 Completed trials

4 Countries active

31 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 2 Phase II/III: 1 Phase II: 9 Phase IV: 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal adenocarcinoma 1 Rectal cancer stage III 1

Top IMPs

TRASTUZUMAB DERUXTECAN 3 4-[1-[[6-[[4-(TRIFLUOROMETHYL)PHENYL]METHYL]-6-AZASPIRO[2.5]OCTANE-7-CARBONYL]AMINO]CYCLOPROPYL]BENZOIC ACID 1 AMIVANTAMAB 1 BALSTILIMAB 1 BOTENSILIMAB 1 CETUXIMAB 1 ENCORAFENIB 1 PANITUMUMAB 1 REGORAFENIB 1 RETIFANLIMAB 1 TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE 1

All trials

13 total

A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending

2025-521209-42-00 Phase IV 3 countries
Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t… Recruiting

2024-519479-24-00 Phase II 4 countries TRASTUZUMAB DERUXTECAN
Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with… Recruiting

2024-515214-41-00 Phase III 1 country
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Phase III 1 country
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie… Recruiting

2023-506662-31-00 Phase II 1 country TRASTUZUMAB DERUXTECAN
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate… Recruiting

2023-503295-25-00 Phase II/III 1 country
Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting

2022-501308-90-00 Phase II 1 country 4-[1-[[6-[[4-(TRIFLUOROMETHYL)PHENYL]METHYL]-6-AZASPIRO[2.5]OCTANE-7-CARBONYL]AM…
Study aimed at testing the activity of a course of chemo-immunotherapy with retifanlimab combined with platinum-etoposide followed by surger… Ended

2024-516316-13-00 Phase II 1 country RETIFANLIMAB
Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric… Ended

2024-518842-26-00 Phase II 1 country
A PHASE 1/2 STUDY EXPLORING THE SAFETY AND ACTIVITY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH CAPECITABINE AND BEVACIZUMAB IN METASTATIC… Ended

2024-513271-41-00 Phase II 1 country TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study Ended

2023-509088-26-00 Phase II 1 country CETUXIMAB; ENCORAFENIB
ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoa… Ended

2024-513297-21-00 Phase II 1 country
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Phase II 1 country PANITUMUMAB; REGORAFENIB

Showing 1–13 of 13 trials

← All sponsors A–Z